The Science Industry Action Agenda is a joint initiative of Science Industry Australia Inc. (SIA) and the Commonwealth government, aimed at maximising the future growth and development of the science industry in Australia

A new technique for examining DNA is giving scientists a more detailed picture of which genes have the propensity for activation, offering a new tool for understanding how genes function and possibly for diagnosing disease

Dr John Raff tells Graeme O'Neill why Australia's agbiotech industry is struggling. [ + ]

One of the leading lights of international stem cell research will be in Australia next week, as a de facto ambassador for Wales as well as to discuss his research. [ + ]

Researchers from the University of Cambridge have made a breakthrough by using supercritical carbon dioxide (scCO2) as a reaction medium for the preparation of molecules of interest to the pharmaceutical industry

Preheating of the mobile phase has been shown to be an important parameter in attaining maximum performance in high temperature liquid chromatography (HTLC)

Clandestine drug laboratories present hazards and dangers to the community in all areas across Australia, including urban and rural centres

The development and widespread adoption of electronic record-keeping and electronic signatures has created unprecedented security challenges for the maintenance and integrity of batch histories in regulated industries

An Australian Law Reform Commission (ALRC) inquiry has found widespread anxiety and uncertainty about whether genetic patents will stifle research and development in the billion-dollar biotech industry

The past two decades have produced a plethora of patents for DNA diagnostic tests to determine people's susceptibility to common, life-threatening disorders like cancer, cardiovascular disease, hypertension and neurodegenerative diseases like Alzheimer's disease and motor neuron disease. [ + ]

The search for faster genomics analysis has spawned a multi-state biotech grid network built from ordinary Windows PCs, reports David Braue. [ + ]

You've run your experiments, got your results, and you've been mentally spending -- or at least licensing -- the proceeds of your bulging IP portfolio. But that may have been the easy part, writes Renate Krelle. Before you go any further, here's a checklist of some of the most common patenting pitfalls. [ + ]

Australia's first ever Cooperative Research Centre is winding up operations. Melissa Trudinger joined its stakeholders for a look back at its successes. [ + ]

Imagine if you could map out your dream lab on the concrete floor -- and then stock it with whatever you wanted. Susan Williamson spoke with Ian Findlay and his team at Gribbles Molecular Science, who did just that. [ + ]

Even after its R&D budget was cut this week by parent company Fonterra, ViaLactia still has one of the biggest research budgets in New Zealand's biotechnology industry. CEO Colin South discussed his company's research programs with Australian Biotechnology News during a tour sponsored by New Zealand Trade and Enterprise in March. [ + ]